Funxional Therapeutics Announces Successful Completion Of The Phase I Programme Of Its Novel Anti-Inflammatory Small Molecule, FX125L
Funxional Therapeutics Ltd (Funxional) has announced the successful completion of the Phase I programme of its novel anti-inflammatory, FX125L, an orally available small molecule that belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs)…
More: continued here
Filed under: Clinical Trials on January 11th, 2010
You must be logged in to post a comment.